Efficacy of sequential treatment with sunitinib-everolimus in an orthotopic mouse model of renal cell carcinoma

Anticancer Research

Volumn 32, Issue 7, 2012, Pages 2399-2406

  Larkin, James ^a   Esser, Norbert ^b   Calvo, Emiliano ^c,d   Tsuchihashi, Zenta ^e   Fiedler, Ulrike ^b   Graeser, Ralph ^b   Kim, Dennis ^f  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b PROQINASE GMBH   (Germany)

^c Hospital Madrid Norte Sanchinarro   (Spain)

^d NOVARTIS PHARMA AG   (Switzerland)

^e Oncology Biomarkers and Clinical Imaging   (United States)

^f Oncology Global Medical Affairs   (United States)

Author keywords

Agents with other mechanisms of action; Animal models of cancer; Cellular responses to anticancer drugs; Genitourinary cancers; Kinase and phosphatase inhibitors; Metastasis; Metastasis genes; Metastasis models; Reversal of drug resistance

Indexed keywords

EVEROLIMUS; LUCIFERASE; SORAFENIB; SUNITINIB;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CANCER TRANSPLANTATION; CONTROLLED STUDY; ENZYME ACTIVITY; EX VIVO STUDY; FEMALE; IN VIVO STUDY; KIDNEY CARCINOMA; METASTASIS; METASTASIS INHIBITION; MOUSE; NONHUMAN; ORTHOTOPIC TRANSPLANTATION; PRIORITY JOURNAL; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; INDOLES; KIDNEY NEOPLASMS; LUCIFERASES; LUMINESCENT MEASUREMENTS; MICE; MICE, INBRED BALB C; PYRROLES; RANDOM ALLOCATION; SIROLIMUS;

EID: 84865686128     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. National Comprehensive Cancer Network (NCCN). The NCCN Clinical Practice Guidelines in Oncology™ for Kidney Cancer V.1.2012. www.nccn/org. Accessed February 10, 2012.
2. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grünwald V, Thompson JA, Figlin RA, Hollaender N, Kay A, Ravaud A; RECORD-1 Study Group: Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 116: 4256-4265, 2010.
3. Molina AM, Feldman DR, Voss MH, Ginsberg MS, Baum MS, Brocks DR, Fischer PM, Trinos MJ, Patil S and Motzer RJ: Phase 1 trial of everolimus plus sunitinib in patients with metastatic renal cell carcinoma. Cancer 118: 1868-1876, 2012.
4. Negrier S, Gravis G, Pérol D, Chevreau C, Delva R, Bay JO, Blanc E, Ferlay C, Geoffrois L, Rolland F, Legouffe E, Sevin E, Laguerre B and Escudier B: Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial. Lancet Oncol 12: 673-680, 2011.
5. Feldman DR, Baum MS, Ginsberg MS, Hassoun H, Flombaum CD, Velasco S, Fischer P, Ronnen E, Ishill N, Patil S and Motzer RJ: Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol 27: 1432-1439, 2009.
6. Di Lorenzo G, Carteni G, Autorino R, Bruni G, Tudini M, Rizzo M, Aieta M, Gonnella A, Rescigno P, Perdonà S, Giannarini G, Pignata S, Longo N, Palmieri G, Imbimbo C, De Laurentiis M, Mirone V, Ficorella C and De Placido S: Phase II study of sorafenib in patients with sunitinib-refractory metastatic renal cell cancer. J Clin Oncol 27: 4469-4474, 2009.
7. Rini BI, Escudier B, Tomczak P, Kaprin A, Szczylik C, Hutson TE, Michaelson MD, Gorbunova VA, Gore ME, Rusakov IG, Negrier S, Ou YC, Castellano D, Lim HY, Uemura H, Tarazi J, Cella D, Chen C, Rosbrook B, Kim S and Motzer RJ: Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 378: 1931-1939, 2011.
8. Garcia JA, Hutson TE, Elson P, Cowey CL, Gilligan T, Nemec C, Dreicer R, Bukowski RM and Rini BI: Sorafenib in patients with metastatic renal cell carcinoma refractory to either sunitinib or bevacizumab. Cancer 116: 5383-5390, 2010.
9. Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG and Kerbel RS: Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 15: 232-239, 2009.
10. Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Viñals F, Inoue M, Bergers G, Hanahan D and Casanovas O: Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15: 220-231, 2009.
11. Hammers HJ, Verheul HM, Salumbides B, Sharma R, Rudek M, Jaspers J, Shah P, Ellis L, Shen L, Paesante S, Dykema K, Furge K, Teh BT, Netto G and Pili R: Reversible epithelial to mesenchymal transition and acquired resistance to sunitinib in patients with renal cell carcinoma: evidence from a xenograft study. Mol Cancer Ther 9: 1525-1535, 2010.
12. Larkin J, Swanton C and Pickering L: Optimizing treatment of metastatic renal cell carcinoma by changing mechanism of action. Expert Rev Anticancer Ther 11: 639-649, 2011.
13. Murphy GP and Hrushesky WJ: A murine renal cell carcinoma. J Natl Cancer Inst 50: 1013-1025, 1973.
14. Bornmann C, Graeser R, Esser N, Ziroli V, Jantscheff P, Keck T, Unger C, Hopt UT, Adam U, Schaechtele C, Massing U and von Dobschuetz E: A new liposomal formulation of gemcitabine is active in an orthotopic mouse model of pancreatic cancer accessible to bioluminescence imaging. Cancer Chemother Pharmacol 61: 395-405, 2008. (Pubitemid 350275974)
15. Workman P, Balmain A, Hickman JA, McNally NJ, Rohas AM, Mitchison NA, Pierrepoint CG, Raymond R, Rowlatt C, Stephens TC and Wallace J: UKCCCR guidelines for the welfare of animals in experimental neoplasia. Br J Cancer 58: 109-113, 1988.
16. Rini BI: Sunitinib. Exp Opin Pharmacother 8: 2359-2369, 2007.
17. Chang YS, Adnane J, Trail PA, Levy J, Henderson A, Xue D, Bortolon E, Ichetovkin M, Chen C, McNabola A, Wilkie D, Carter CA, Taylor IC, Lynch M and Wilhelm S: Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models. Cancer Chemother Pharmacol 59: 561-574, 2007. (Pubitemid 46295136)
18. O'Reilly T and McSheehy PM: Biomarker development for the clinical activity of the mTOR inhibitor everolimus (RAD001): processes, limitations, and further proposals. Translational Oncol 3: 65-79, 2010.
19. Killion JJ, Radinsky R and Fidler IJ: Orthotopic models are necessary to predict therapy of transplantable tumors in mice. Cancer Metastasis Rev 17: 279-284, 1998. (Pubitemid 29210167)
20. Morgensztern D and McLeod HL: PI3K/Akt/mTOR pathway as a target for cancer therapy. Anticancer Drugs 16: 797-803, 2005. (Pubitemid 41215743)
21. Rini BI: Vascular endothelial growth factor-targeted therapy in metastatic renal cell carcinoma. Cancer 115: 2306-2312, 2009.
22. Ranieri G, Patruno R, Ruggieri E, Montemurro S, Valerio P and Ribatti D: Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: From the biology to the clinic. Curr Med Chem 13: 1845-1857, 2006.
23. Mancuso MR, Davis R, Norberg SM, O'Brien S, Sennino B, Nakahara T, Yao VJ, Inai T, Brooks P, Freimark B, Shalinsky DR, Hu-Lowe DD and McDonald DM: Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest 116: 2610-2621, 2006. (Pubitemid 44511625)
24. Lane HA, Wood JM, McSheehy PM, Allegrini PR, Boulay A, Brueggen J, Littlewood-Evans A, Maira SM, Martiny-Baron G, Schnell CR, Sini P and O'Reilly T: mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor. Clin Cancer Res 15: 1612-1622, 2009.
25. Fuereder T, Jaeger-Lansky A, Hoeflmayer D, Preusser M, Strommer S, Cejka D, Koehrer S, Crevenna R and Wacheck V: mTOR inhibition by everolimus counteracts VEGF induction by sunitinib and improves anti-tumor activity against gastric cancer in vivo. Cancer Lett 296: 249-256, 2010.
26. Huang D, Ding Y, Li Y, Luo WM, Zhang ZF, Snider J, Vandenbeldt K, Qian CN and Teh BT: Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma. Cancer Res 70: 1053-1062, 2010.
27. Grünwald V, Karakiewics PI, Bavbek SE, Miller K, Machiels JP, Lee SH, Larkin J, Bono P, Rha SY, Castellano D, Blank CU, Knox JJ, Hawkins R, Anak O, Rosamilia M, Booth J, Pirotta N, Bodrogi I; REACT Study Group: An international expandedaccess programme of everolimus: Addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy. Eur J Cancer 48: 324-332, 2012.
28. Calvo E, Escudier B, Motzer RJ, Oudard S, Hutson TE, Porta C, Bracarda S, Grünwald V, Thompson JA, Ravaud A, Kim D, Panneerselvam A, Anak O and Figlin RA: Everolimus in metastatic renal cell carcinoma: Subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptortyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study. Eur J Cancer 48: 333-339, 2012.